Sun Pharma Reinforces Position As Indian Industry Leader
Trajectory Expected To Continue Amid R&D Cost Rise
Executive Summary
Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.
You may also be interested in...
Sun Forwards Specialty Strategy With $576m Concert Acquisition
Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.
PBMs’ ‘Perverse Incentives’ Still Limiting Generics Access, AAM Report Reiterates
Generic medicines continue to be intentionally left off formulary tiers in favor of more expensive brand medications, according to a new report from the US Association for Accessible Medicines.
Generic Mifepristone Manufacturer Sues West Virginia Over Abortion Ban
Generic abortion pill manufacturer GenBioPro has mounted a case in West Virginia alleging that its state-level ban of abortion is unconstitutional, as it is pre-empted by the US Food and Drug Administration’s federal opinion that mifepristone is a safe and legal medication.